Table 1.
APL patients’ laboratory characteristics
| Characteristics | Control (n = 28) | APL (n = 40) |
|---|---|---|
| Age (y) | 42.4 ± 5.12 | 40.6 ± 10.8 |
| Male sex, n (%) | 12 (42.9%) | 17 (42.5%) |
| Diagnosis | ||
| M3/bcr1, n (%) | — | 23 (57.5%) |
| M3/bcr2, n (%) | — | 7 (17.5%) |
| M3/bcr3, n (%) | — | 10 (25%) |
| WBC (×109) | 6.5 (5.2-7.9) | 10.8 (4.3-24.8) |
| Hb (g/L) | 132.5 (118-138) | 68.6 (60.6-80.8)* |
| PLTs (×109) | 230 (195.8-256.8) | 21.2 (12.0-31.1)* |
| Blasts (BM %) | — | 86.3 (82.6-90.0) |
| PT (s) (r.v.10-15) | 12.7 (11.5-13.6) | 16.1 (13.8-18.7)* |
| APTT (s) (r.v.20-40) | 33.0 (30.1-35.6) | 27.5 (23.8-32.9)* |
| Fibrinogen (g/L) | 2.9 (2.5-3.5) | 1.4 (1.2-1.9)* |
| D-dimer (µg/mL) | 0.25 (0.17-0.30) | 2.50 (0.99-3.53)* |
| Hemorrhage (+), n (%) | — | 31 (77.5%) |
The main clinical and laboratory features of 28 healthy controls and 40 newly diagnosed APL patients at the moment of bone marrow aspiration are reported. Hemorrhage was manifested as mucosal bleeding, spontaneous ecchymoses, petechiae, hematemesis, hematuria, melena, or menorrhagia. Data are presented as numbers (percentages) or median ± standard deviation (SD) or median values (25th and 75th percentiles).
APTT, activated partial thromboplastin time; bcr, breakpoint cluster region (bcr1 = intron 6, bcr2 = exon 6, bcr3 = intron 3); Blasts, promyelocytes + blasts; BM, bone marrow; Hb, hemoglobin; PLT, platelet; PT, prothrombin time; WBC, white blood cell.
*
P < .001 vs healthy control.